• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy
    Subscribe to $MAIA

    MAIA Biotechnology Inc.

    Subscribe to $MAIA
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    IPO Year: 2022

    Exchange: AMEX

    Recent Analyst Ratings for MAIA Biotechnology Inc.

    DatePrice TargetRatingAnalyst
    See more ratings

    MAIA Biotechnology Inc. Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/5/25 4:42:27 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Guerrero Ramiro bought $30,000 worth of shares (20,000 units at $1.50), increasing direct ownership by 4% to 588,218 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    5/12/25 4:14:02 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $99,999 worth of shares (66,666 units at $1.50) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    5/12/25 4:12:43 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Guerrero Ramiro bought $50,000 worth of shares (33,333 units at $1.50), increasing direct ownership by 6% to 568,218 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    3/5/25 4:42:20 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $37,500 worth of shares (25,000 units at $1.50) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    3/5/25 4:40:57 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Smith Stan bought $75,000 worth of shares (50,000 units at $1.50) (SEC Form 4)

    4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    3/5/25 4:39:20 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: Director Guerrero Ramiro bought $110,000 worth of shares (73,333 units at $1.50), increasing direct ownership by 16% to 534,885 units (SEC Form 4)

    4/A - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    3/5/25 4:37:22 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Guerrero Ramiro bought $110,000 worth of shares (73,333 units at $1.50), increasing direct ownership by 16% to 534,885 units (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    2/25/25 4:11:24 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $75,000 worth of shares (50,000 units at $1.50) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    2/25/25 4:10:22 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $46,800 worth of shares (25,000 units at $1.87) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    12/13/24 5:17:59 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Guerrero Ramiro

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:17:45 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Chaouki Steven M

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:16:50 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Louie Ngar Yee

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:16:10 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Smith Stan

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:14:56 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Luput Cristian

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:13:57 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Theagene Jean-Manasse

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    7/2/25 4:13:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Smith Stan bought $50,000 worth of shares (33,333 units at $1.50) (SEC Form 4)

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    6/5/25 4:42:27 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Executive Officer Vitoc Vlad

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    5/16/25 4:15:26 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Gryaznov Sergei

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    5/16/25 4:14:36 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Head of Finance Himmelreich Jeffrey C

    4 - MAIA Biotechnology, Inc. (0001878313) (Issuer)

    5/16/25 4:13:34 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. SEC Filings

    View All

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    9/24/25 8:25:30 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    9/18/25 5:14:45 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    9/12/25 4:05:49 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by MAIA Biotechnology Inc.

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    9/11/25 4:05:45 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    9/8/25 6:11:22 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    8/13/25 9:15:16 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by MAIA Biotechnology Inc.

    10-Q - MAIA Biotechnology, Inc. (0001878313) (Filer)

    8/11/25 7:31:15 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    7/28/25 8:15:28 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    7/17/25 4:05:38 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. filed SEC Form 8-K: Financial Statements and Exhibits

    8-K - MAIA Biotechnology, Inc. (0001878313) (Filer)

    7/9/25 4:05:59 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. Leadership Updates

    Live Leadership Updates

    View All

    MAIA Biotechnology Welcomes Leading Hepatocellular Carcinoma Clinician-Scientists to Scientific Advisory Board

    Planning for Phase 2 clinical trial in hepatocellular carcinoma (HCC) underway MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced the appointment of two prominent oncologists to its Scientific Advisory Board (SAB), Claudia Fulgenzi, MD, and David J. Pinato, MD, MRCP (UK), PhD. Both are specialists in hepatocellular carcinoma (HCC), a tumor type to be studied in future clinical trials of MAIA's lead candidate ateganosine (THIO) sequenced with a checkpoint inhibitor. As SAB members they will advise MAIA on designs and protocols for its company sponsored trial (C

    6/24/25 8:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Poster Presentation at ESMO's European Lung Cancer Congress 2025

    Poster highlights potential predictive biomarker for therapeutic response in advanced non-small cell lung cancer (NSCLC)   MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that an abstract detailing a potential predictive biomarker for THIO treatment was selected for poster presentation at the European Lung Cancer Congress 2025 (ELCC 2025) taking place, March 26-29, in Paris, France. ELCC is a program of the European Society for Medical Oncology (ESMO). "We are proud to join ELCC 2025, a premier conference focused directly on the science of thoracic oncology," said V

    3/25/25 8:46:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Welcomes Prominent Medical Oncology Scientist Dr. Saadettin Kilickap to its Scientific Advisory Board

    Acclaimed academic researcher has led 40+ multicenter phase 2 and phase 3 clinical studies MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of Professor Saadettin Kilickap, M.D. to its Scientific Advisory Board (SAB). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240321173734/en/Professor Saadettin Kilickap, M.D., Scientific Advisor to MAIA Biotechnology (Photo: Business Wire) Dr. Kilickap is a professor at the Istinye University Faculty of Medicine, Department of Medical Oncology, Liv Hos

    3/21/24 3:00:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Appoints Leading Immuno-Oncology Scientist Dr. Remus Vezan as Scientific Advisor

    New Scientific Advisory Board member played instrumental role in FDA approval and commercialization of multiple blockbuster products CHICAGO, IL, Feb. 27, 2024 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced the appointment of immuno-oncology leader Remus Vezan, M.D., Ph.D., to its Scientific Advisory Board (SAB). With over 20 years of academic and biopharmaceutical industry experience, Dr. Vezan is a highly regarded leader in drug development of novel therapeutic modalities, including cell and gene therapies, and played a pivotal role in the devel

    2/27/24 10:30:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by MAIA Biotechnology Inc.

    SC 13D/A - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 6:16:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:12:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by MAIA Biotechnology Inc.

    SC 13D - MAIA Biotechnology, Inc. (0001878313) (Subject)

    10/25/24 5:10:55 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MAIA Biotechnology Inc.

    SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

    2/14/23 12:00:03 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MAIA Biotechnology Inc.

    SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

    2/14/23 11:37:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by MAIA Biotechnology Inc.

    SC 13G - MAIA Biotechnology, Inc. (0001878313) (Subject)

    2/14/23 11:35:59 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Inc. Press Releases

    Fastest customizable press release news feed in the world

    View All

    MAIA Biotechnology Announces $2.25 Million Private Placement

    CHICAGO, IL, Sept. 29, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc., (NYSE: MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer, today announced that it has entered into definitive agreements for the purchase and sale of an aggregate of 1,733,766 shares of common stock at a purchase price of $1.30 per share, in a private placement to accredited investors and a Company director. Each share of common stock is being offered together with a warrant to purchase one share of common stock at an exercise price of $1.57 per share, which price represents the "Minimum Price" as defined under NYSE American Rule 713 (subject to c

    9/29/25 4:30:00 PM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Awarded $2.3 Million Grant by National Institutes of Health for THIO-101 Phase 2 Trial of Cancer-Fighting Agent

    THIO-101 Phase 2 trial to enroll patients in the U.S. as part of the expansion of the study in third-line treatment for advanced non-small cell lung cancer (NSCLC) CHICAGO, Sept. 24, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, announced today that the National Institutes of Health (NIH) has awarded a $2.3 million grant for the expansion of its THIO-101 Phase 2 clinical trial evaluating ateganosine as a third-line treatment for patients with advanced non-small cell lung cancer (NSCLC).  The grant is intended to support expenses related to the enr

    9/24/25 8:01:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Highlights Positive Efficacy Data from THIO-101 Phase 2 Clinical Trial in Non-Small Cell Lung Cancer

    CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today highlighted positive efficacy data from its Phase 2 clinical trial, THIO-101, evaluating ateganosine (THIO) sequenced with the immune checkpoint inhibitor (CPI) cemiplimab (Libtayo®) in patients with advanced non-small cell lung cancer (NSCLC) who had failed two or more standard-of-care therapy regimens. As of June 30, 2025, Estimated median progression free survival (PFS) in third-line treatment (180 mg dose) was 5.6 months. The comparable PFS threshold in standard of care tre

    9/11/25 9:27:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Abstract Selected for Poster Presentation at 2025 IASLC World Conference on Lung Cancer

    Poster details durability and efficacy of ateganosine (THIO) treatment in non-small cell lung cancer (NSCLC) CHICAGO, Sept. 05, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that an abstract titled "Study of THIO Sequenced with Cemiplimab in 3rd Line Immune Checkpoint Inhibitor-resistant aNSCLC: Improvement in PFS" was selected for poster presentation at the 2025 IASLC World Conference on Lung Cancer (WCLC) taking place September 6–9, 2025, in Barcelona, Spain. "We are proud to accept IASLC's invitation to present our exceptional a

    9/5/25 9:03:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces Publication of Interim Clinical Data on Telomere Targeting Anticancer Agent in Peer-Reviewed Journal Cells

    CHICAGO, Aug. 27, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that a manuscript detailing developments in its Phase 2 THIO-101 clinical trial was accepted and published in the international peer-reviewed open access scientific journal, Cells, in a special issue, "Cellular Mechanisms of Anti-Cancer Therapies" The manuscript, titled "Perioperative Management of Non-Small Cell Lung Cancer in the Era of Immunotherapy," was authored by a group of oncology researchers in Turkey and the U.S. including MAIA scientists Sergei Gryaznov, Ph.

    8/27/25 9:01:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Diamond Equity Research Releases Update Note on MAIA Biotechnology, Inc. (NYSE: MAIA)

    New York, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Diamond Equity Research, a leading equity research firm with a focus on small capitalization public companies has released an update note on MAIA Biotechnology, Inc. (NYSE:MAIA) following quarterly results. The update note includes detailed information on the MAIA Biotechnology's business, recent updates, management commentary, financial results, valuation, and risks. The full update note is available below. MAIA Biotechnology August 2025 Update Note Highlights from the note include:                                               Strengthens Clinical Momentum in Q2 2025 with Strong Phase 2 NSCLC Survival Data, Fast Track Designation, Global T

    8/18/25 8:00:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Granted European Patent for Next Generation Telomere-Targeting Agents for Cancer Therapy

    Cancer-fighting immunosuppressive agents shown to disrupt telomeres and suspend growth of cancer cells  CHICAGO , Aug. 13, 2025 (GLOBE NEWSWIRE) -- MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the European Patent Office has decided to grant a patent broadly covering a portfolio of ateganosine-based analogues for telomere-targeting anticancer therapy and methods of using ateganosine (THIO) alone or before administration of checkpoint inhibitors (CPIs). The patent, titled "Mercaptopurine Ribonucleoside Analogues for Altering Telomerase Mediated Telomere

    8/13/25 9:01:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Receives FDA's Fast Track Designation for Ateganosine as a Treatment for Non-Small Cell Lung Cancer

    Potential first-to-market small molecule telomere targeting agent targets a $34 billion NSCLC treatment market Latest data in pivotal Phase 2 THIO-101 clinical trial shows median overall survival of 17.8 months MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for ateganosine (THIO, 6-thio-dG or 6-thio-2'-deoxyguanosine) for the treatment of non-small cell lung cancer (NSCLC). Ateganosine is currently being evaluated in a pivotal Phase 2 THIO-101 clinical trial evaluating its

    7/28/25 8:01:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology Announces First Patient Dosed in Expansion of Phase 2 Trial for Ateganosine in Advanced Non-Small Cell Lung Cancer

    MAIA Biotechnology, Inc. (NYSE:MAIA), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced dosing of the first patient in Taiwan in the expansion phase of its THIO-101 Phase 2 trial for advanced non-small cell lung cancer (NSCLC). The trial's entry into another continent marks a key milestone for MAIA, opening a significantly larger patient pool for its evaluations of ateganosine (THIO). Screening for the trial is ongoing in Europe and Asia. Trial Design: The expansion study evaluates ateganosine in heavily pre-treated patients in third-line (3L) NSCLC who have previously failed treatment with checkpoint inhibitors (CPIs) an

    7/9/25 9:15:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    MAIA Biotechnology to Present Two Posters Featuring Cancer Telomere-Targeting Agents at FEBS 2025 Congress

    MAIA Biotechnology, Inc. (NYSE:MAIA) ("MAIA", the "Company"), a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer, today announced two upcoming poster presentations at the 49th Federation of European Biochemical Societies (FEBS) 2025 Congress, hosted by the Turkish Biochemical Society, to be held July 5-9, 2025, in Istanbul, Turkey. The poster presentations highlight MAIA's lead telomere-targeting agent and next-generation treatments. The first presentation will be delivered by MAIA Scientific Advisory Board member, Z. Gunnur Dikmen, M.D., Ph.D., Hacettepe University, Faculty of Medicine, Department of Biochemistry in Ankara, Turkey. Poster

    7/1/25 9:00:00 AM ET
    $MAIA
    Biotechnology: Pharmaceutical Preparations
    Health Care